| Outcome Measures: |
Primary: Assessment of Pharmacokinetic (PK) Parameter: AUC, Sotagliflozin: Area under the concentration-time curve from 0 to infinity (AUC) for reference, p1, p2, and p3 formulations, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: Area under the concentration-time curve from 0 to last quantifiable concentration (AUClast), Sotagliflozin: Area under the concentration-time curve from 0 to last quantifiable concentration for reference, p1, p2, and p3 formulations, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: Maximum plasma concentration (Cmax), Sotagliflozin: Maximum plasma concentration (Cmax) for reference, p1, p2, and p3 formulations, From 0 to 144 hours after IMP intake | Secondary: Assessment of PK Parameter: Tmax, Sotagliflozin: Time to reach maximum plasma concentration (Tmax), From 0 to 144 hours after investigational medicinal product (IMP) intake|Assessment of PK Parameter: Time to reach AUClast (Tlast), Sotagliflozin: Time to reach AUClast, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: Terminal elimination half-life (t1/2), Sotagliflozin: Terminal elimination half-life (t1/2), From 0 to 144 hours after IMP intake|Assessment of PK Parameter: Tmax, Sotagliflozin 3-O-glucuronide: Tmax, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: Tlast, Sotagliflozin 3-O-glucuronide: Time to reach AUClast, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: t1/2, Sotagliflozin 3-O-glucuronide: t1/2, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: Cmax, Sotagliflozin 3-O-glucuronide: Cmax, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: AUC, Sotagliflozin 3-O-glucuronide: AUC, From 0 to 144 hours after IMP intake|Assessment of PK Parameter: AUClast, Sotagliflozin 3-O-glucuronide: AUClast, From 0 to 144 hours after IMP intake|Adverse Events, Number of patients with treatment emergent adverse events (serious and non-serious), Up to 75 days
|
